AstraZeneca will co-develop stem cell drugs for diabetic blindness

09/12/2010 | Guardian (London), The

AstraZeneca signed a three-year research agreement with the University College London's Institute of Ophthalmology to discover and develop stem-cell-based drugs to treat diabetic retinopathy. "We're getting very keen on the whole area of regenerative medicines, and they will be part of our research development over the next few years," an AstraZeneca official said.

View Full Article in:

Guardian (London), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI